Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

San Diego Biotechnology Network
San Diego Biotechnology Network
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
Loading
/

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from September 27 through October 1, 2019.